Shalabh Gupta
CEO,
Unicycive Therapeutics
United States
Shalabh Gupta, MD, founded Unicycive and has served as Chief Executive Officer, President, and director since August 2016. Previously, Dr. Gupta served in various other roles, including founder and Chief Executive Officer of Biocycive Inc.; a commercial strategist at Genentech, Inc.; equity researcher covering US pharmaceutical companies at UBS Investment Bank; and as an equity researcher covering biotechnology companies at Rodman & Renshaw (currently HC Wainwright). Dr. Gupta previously served as a medical advisor to Synageva BioPharma Corporation and as an advisor to New York University (NYU) Langone Medical Center’s Office of Technology Transfer. Dr. Gupta is also the founder and Chief Executive Officer of Globavir, a company with a diagnostic platform technology licensed from Stanford University, which partnered with Bio-Rad (NASDAQ: BIO) in 2016 and later with Cepheid (now part of Danaher Corporation, NYSE: DHR). Bio-Rad currently sells this technology as part of their RUO (Research Use Only) kits, and Danaher is advancing diagnostic technology through the regulatory approval process worldwide. Before his roles in business and finance, Dr. Gupta was an attending physician at New York University (“NYU”) Medical Center and a clinical faculty member at the NYU School of Medicine. Dr. Gupta was a board-certified physician.
)
){kind=logo}
)
){kind=logo}
){kind=logo}